Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Urology That Protect the Ancillary Engine and the Margin It Drives

Urology's economics run far beyond the office visit — through buy-and-bill drugs, in-office procedures, pathology, imaging, lithotripsy, and the ASC. Fulcrum Health Partners advises independent groups, integrated prostate-cancer platforms, and PE- and MSO-backed organizations on commercial rate strategy, Part B drug and ASP economics, site-of-service and prior-authorization pressure, and revenue integrity. We convert a complex ancillary footprint into durable, defensible enterprise value.

Model Your Reimbursement Opportunity → Speak with a Urology Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

The Urology Reimbursement Landscape

The professional fee is the smaller half. The margin lives in the ancillaries.

In urology, the office visit and surgical fee are only the entry point — the economics that decide the enterprise sit in buy-and-bill drugs, in-office procedures, pathology, imaging, lithotripsy, and the ASC.

A modern urology group is effectively a diagnostics-and-therapeutics business wrapped around a physician panel. Part B drug buy-and-bill — leuprolide and other LHRH agonists, advanced prostate-cancer agents, and intravesical BCG — carries meaningful revenue but thin, ASP-driven margins that move with every quarterly pricing update. In-office procedures such as cystoscopy, prostate biopsy, UroLift, and Rezum, together with integrated pathology, lab, imaging, and lithotripsy, layer on ancillary income that competitors without the same footprint cannot match.

That concentration is also the exposure. Site-of-service differentials pull cases between office, ASC, and hospital outpatient; prior authorization on multiparametric MRI, PSMA-PET, drugs, and procedures throttles throughput; and payer policy quietly reprices the very services that fund the practice. As large PE- and MSO-backed platforms consolidate urology into national groups, the same book of business can be worth dramatically different amounts depending on how it is coded, contracted, and defended — and that is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology, ASP files, and public payer data, 2024–2026.

Revenue Composition, Urology Group — Illustrative

Where the margin actually sits

The visit is a fraction of the picture. Fulcrum quantifies the full stack — drug, procedure, ancillary, and ASC — and defends its reimbursement.

ASP+

Part B drug payment resets every quarter

~50%

Of urology revenue can sit outside the professional fee

65+

Median urology patient age skews toward Medicare & MA

PSMA

Advanced imaging & drugs now gated by prior authorization

Reimbursement Intelligence in Action

Your practice economics, by urology profile

Fulcrum turns your claims, drug-purchasing, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view spanning professional fees, in-office procedures, and Part B drug and ancillary revenue.

Independent Urology Group · Payer Mix & Revenue Live Sample

Payer Mix (by active patients)

Net Revenue by Payer — Professional/FFS vs. Drug & Ancillary

Professional & FFS net paymentsPart B drug buy-and-bill & ancillary revenue

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, drug-purchasing, and contract data by CPT/HCPCS, payer, and contract.

The Forces Reshaping Urology Economics

The strategic questions every urology leader now faces

Beyond the fee schedule, these are the dynamics that decide urology margin — and where Fulcrum builds the strategy.

Part B Drug Buy-and-Bill & ASP Dynamics

Protecting margin on LHRH agonists, advanced prostate-cancer agents, and intravesical BCG as ASP resets, biosimilars, and payer step therapy compress spread.

Site-of-Service & ASC Migration

Managing payer differentials that shift cystoscopy, stone, and prostate procedures across office, ASC, and hospital outpatient — and capturing the facility economics.

In-Office Ancillary Economics

Defending the reimbursement of integrated pathology, lab, imaging, lithotripsy, and prostate-cancer radiation that differentiate the platform.

Prior Authorization on Imaging, Drugs & Procedures

Reducing the administrative tax and denial leakage on multiparametric MRI, PSMA-PET, advanced agents, and elective procedures.

PE & MSO Platform Consolidation

Competing with — and evaluating alignment into — the large national urology platforms now rolling up independent groups and their ancillaries.

Medicare Advantage & the Declining Conversion Factor

Absorbing real-terms cuts to physician payment while an aging, MA-heavy urology panel shifts leverage toward managed-care negotiation.

Our Urology Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide urology margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract, fee schedule, and drug-reimbursement term, then benchmark your urology rates — professional, procedural, ancillary, and Part B drug — against Medicare and against market using proprietary intelligence, quantifying exactly where you sit and what the opportunity is worth.

Contract digitization

Fee schedule normalization

% of Medicare benchmarking

Buy-and-bill & ASP margin analysis

Ancillary & ASC rate analysis

EOB & payment variance analysis

Underpayment identification

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to improve commercial rates, drug-administration and ancillary terms, and site-of-service economics across every payer — from renewals to executive payer meetings.

Commercial rate improvement

Contract renewals & redlining

MA & Medicaid managed care

Drug & ancillary term strategy

Escalation & executive strategy

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT- and HCPCS-level modeling that turns claims, drug purchasing, and contracts into scenario analysis, site-of-service comparisons, and revenue forecasts your executives can act on.

CPT/HCPCS reimbursement modeling

Buy-and-bill margin scenarios

Payer mix & revenue forecasting

Office vs. ASC site-of-service modeling

Fee schedule comparison

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing urology groups and ASCs are actually paid — for procedures, drugs, and ancillaries — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Drug & procedure rate positioning

Negotiation preparation

Peer & ASC comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers

Covered Lives & Market Intelligence

We map covered lives, payer penetration, referral patterns, and network adequacy across your market so you prioritize the negotiations and ancillary investments that move the most margin.

Covered-lives analysis

Payer penetration & market share

Referral & catchment dynamics

Network adequacy leverage

Employer & population trends

Commercial opportunity identification

06 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers deny advanced imaging and drugs, downcode procedures, or misapply site-of-service and drug-administration terms, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Prior-auth & medical-necessity appeals

Downcoding & policy challenges

Drug & site-of-service disputes

Escalation support

Contract enforcement

07 The Challenge — Earned revenue that never arrives — and dollars paid back that shouldn't be

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, ASP files, allowables, and EOB/remittance data to detect variances in both directions — recovering underpaid procedures, drugs, and ancillaries, defending against improper recoupments, and fixing the root cause so leakage stops.

Contract compliance auditing

Underpayment & variance detection

Overpayment & recoupment defense

Buy-and-bill & ASP reconciliation

Automated EOB/remit analytics

Recovery & appeals strategy

Root-cause remediation

Revenue integrity programs

Ancillary charge-capture review

Urology Reimbursement Calculator

See what an optimized urology book is worth

Model the annual uplift from moving commercial professional and procedural rates toward market levels while recovering margin on Part B drug buy-and-bill, in-office procedures, and the ASC. All figures are illustrative and additive.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual commercial professional & procedure revenue

Current commercial rate (% of Medicare)

Optimized commercial rate (% of Medicare) — 130%

Annual Part B drug buy-and-bill & ancillary revenue

Recoverable buy-and-bill, ancillary & ASC margin (%)

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of addressable revenue

3-year cumulative

Directional estimate for discussion only. Combines commercial professional/procedure rate improvement with recoverable margin on Part B drug buy-and-bill, in-office ancillaries, and the ASC. A Fulcrum analysis models your actual contracts, ASP economics, and payer mix.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with urology groups, ancillary platforms, and PE- and MSO-backed organizations.

Independent Urology Group

17%

commercial rate improvement

Situation: A single-specialty group discovered its commercial procedure rates trailed the market with no data to prove it. Result: Transparency-file benchmarking repositioned the group and lifted blended commercial reimbursement across its top payers — without adding a single case.

Integrated Prostate-Cancer Platform

$5.2M

recovered drug & ancillary revenue

Situation: Buy-and-bill margins and pathology, imaging, and radiation revenue were eroding under ASP resets and denials. Result: ASP reconciliation, charge-capture repair, and prior-auth remediation recovered leaked revenue and stabilized the ancillary engine.

PE-/MSO-Backed Platform

8 pts

margin from contract harmonization

Situation: A multi-state roll-up inherited a patchwork of legacy urology contracts and site-of-service terms. Result: Harmonized rates, aligned ASC economics, and recovered systematic underpayments — lifting EBITDA ahead of a recapitalization.

Why Urology Leaders Choose Fulcrum

The advisor that speaks urology's economic language

Independent by design and fluent in the economics of the ancillary-driven practice — buy-and-bill and ASP, in-office procedures, pathology, imaging, lithotripsy, the ASC, and commercial rate strategy — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Urology & Ancillary Fluency

Fluent in the drug, procedure, and ancillary lines that fund the practice.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

Buy-and-Bill & ASP Analytics

Modeling down to the HCPCS code and the ASP reset.

National Payer Experience

Insight into payer policy in every market.

Site-of-Service & ASC Insight

Positioning for office, ASC, and hospital differentials.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Urology insights & analysis

Executive briefings on the forces moving urology economics — buy-and-bill and ASP dynamics, site-of-service and ASC migration, prior authorization on advanced imaging and drugs, and platform consolidation.

Defending Buy-and-Bill Margin as ASP Resets → Site-of-Service & the Urology ASC Opportunity →

Explore Urology Insights →